Key Events This Week
16 Mar: Stock hits all-time low near Rs.0.55
19 Mar: New 52-week and all-time low recorded at Rs.0.54
20 Mar: Stock rebounds with a 5.36% daily gain to Rs.0.59
Jun 09, 03:30 PM
BSE+NSE Vol: 4.11 lacs
Shree Ganesh Biotech India Ltd's latest financial results for the quarter ended March 2026 reflect significant operational challenges. The company reported a net profit loss of ₹0.15 crores, which represents a swing from a profit of ₹0.32 crores in the previous quarter, indicating a deterioration in profitability. This loss is accompanied by a deeply negative operating margin of -20.28%, which highlights ongoing issues in converting revenue into profit. Despite a sequential revenue increase of 202.86% to ₹2.12 crores from ₹0.70 crores in the previous quarter, the year-on-year revenue shows a decline of 29.57% from ₹3.01 crores in the same quarter last year. This volatility raises concerns about the sustainability of revenue growth and the company's ability to maintain a stable customer base. The company's operational performance has been marked by persistent losses, with negative operating margins recorde...
Read full news article
Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Aug 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Shree Ganesh Biotech India Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹24.32 crores, reported a net loss of ₹0.15 crores in Q4 FY26 (Mar'26), marking a sharp deterioration from the ₹0.32 crores profit posted in the previous quarter. The stock, currently trading at ₹0.61, has declined 34.41% over the past year, significantly underperforming the broader market and reflecting mounting investor concerns over the company's operational viability.
Read full news articleThe next results date for Shree Ganesh Biotech India Ltd is scheduled for 14 May 2026....
Read full news article
Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Aug 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 17 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
The micro-cap pharmaceutical company Shree Ganesh Biotech India Ltd has plunged to a fresh all-time low of Rs.0.54 on 1 Apr 2026, extending a multi-year decline that has seen its share price lose over 90% in the past five years. Despite a modest rebound in recent sessions, the stock remains deeply undervalued and faces significant headwinds across valuation and financial metrics.
Read full news article
The micro-cap pharmaceutical stock Shree Ganesh Biotech India Ltd has plunged to an all-time low of Rs 0.54 on 30 Mar 2026, marking a fresh nadir amid a prolonged downtrend that has seen the share price lose nearly 39% over the past year.
Read full news article
The shares of Shree Ganesh Biotech India Ltd have plunged to an all-time low of Rs 0.54 on 25 Mar 2026, extending a steep decline that has seen the stock lose over 43% in the past year despite a flat recent financial performance.
Read full news article